Respiratory Microbiota and Immune Response in CVID

Boston University

Status: Enrolling

Conditions: CVID

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT06173128

H-42779

Details and patient eligibility

About

Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency. Respiratory ailments are the most frequent complications of CVID, with chronic pulmonary disease developing in 30-60% and even more experiencing frequent acute respiratory infections. This project aims to establish cutting-edge approaches to study pulmonary biology in CVID and apply novel bioinformatics strategies to study complex interactions among microbes and host cells by direct sampling of the respiratory tract. The central hypothesis for this research is that antibody (Ab) deficiency in CVID alters respiratory microbiota and host interactions to drive pulmonary disease.

Enrollment: 80 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients with primary antibody deficiency diagnosed by their treating physician
• Controls will not have a diagnosis of immunodeficiency of any sort
• Male and female patients will be enrolled evenly

Exclusion criteria

• Patients who self identify as pregnant
• Patients with asthma or chronic obstructive pulmonary disease (COPD) that are not well controlled clinically

Trial design

80 participants in 2 patient groups

Antibody deficient participants

Description:

Provider referred patients that have antibody deficiency.

Controls

Description:

Patients without antibody deficiency from the allergy and immunology clinic at Boston Medical Center and from healthy volunteers at the BU School of Medicine.